NAT10 and hepatocellular carcinoma: The results suggested that HCC patients with high NAT10 expression had significantly lower OS (overall survival), PPS (post-progression survival), and DSS (disease-specific survival) than HCC patients with low NAT10 expression (Fig. 1C).